Imexpharm (STC:IMP) Beginning Cash Position: ₫189,538 Mil (As of Mar. 2026)


STC:IMP Imexpharm Corp STC:IMP
97 GF Score
Price ₫41,700.00
GF Value ₫52,426.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Beginning Cash Position?

Imexpharm STC:IMP -0.24% 97 Beginning Cash Position is ₫189,538 Mil as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 97/100 and a GF Value™ of ₫52,426.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Imexpharm's Beginning Cash Position for the quarter that ended in Mar. 2026 was ₫189,538 Mil.

Imexpharm's quarterly Beginning Cash Position declined from Sep. 2025 (₫261,694 Mil) to Dec. 2025 (₫173,621 Mil) but then increased from Dec. 2025 (₫173,621 Mil) to Mar. 2026 (₫189,538 Mil).

Imexpharm's annual Beginning Cash Position declined from Dec. 2023 (₫178,845 Mil) to Dec. 2024 (₫106,201 Mil) but then increased from Dec. 2024 (₫106,201 Mil) to Dec. 2025 (₫161,983 Mil).

Imexpharm Beginning Cash Position Related Terms

Imexpharm Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Imexpharm's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Beginning Cash Position Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85,268.71 271,272.87 178,845.07 106,200.57 161,983.38

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 161,983.32 303,022.33 261,694.11 173,621.18 189,537.67
STC:IMP
97GF Score
Imexpharm Corp STC:IMP
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ₫189,538 Mil mean?
Imexpharm (STC:IMP) has a Beginning Cash Position of ₫189,538 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Imexpharm and its competitors.
Is Imexpharm's Beginning Cash Position too high?
Imexpharm's current Beginning Cash Position is ₫189,538 Mil. Overall, Imexpharm has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Beginning Cash Position compare to ZTS and UTHR?
Imexpharm's Beginning Cash Position of ₫189,538 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Imexpharm and its competitors. Imexpharm's current Beginning Cash Position is ₫189,538 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫52,426.51, compared to a current price of ₫41,700.00 — trading 20.5% below its estimated fair value. The current Beginning Cash Position is ₫189,538 Mil. Imexpharm's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Beginning Cash Position is ₫189,538 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫41,700.00 is trading 20.5% below its estimated GF Value™ of ₫52,426.51. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Beginning Cash Position: ₫189,538 Mil
  • GF Value™: ₫52,426.51 vs. price of ₫41,700.00 (20.5% below fair value)
  • GF Score™: 97/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
97GF Score

Get the complete analysis for STC:IMP

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫41,700.00
Price
₫52,426.51
GF Value